Endogenous mono-ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression

Eur J Biochem. 2003 Jan;270(1):101-10. doi: 10.1046/j.1432-1033.2003.03366.x.

Abstract

ADP-ribosylation has been coupled to intracellular events associated with smooth muscle cell vasoreactivity, cytoskeletal integrity and free radical damage. Additionally, there is evidence that ADP-ribosylation is required for smooth muscle cell proliferation. Our investigation employed selective inhibitors to establish that mono-ADP-ribosylation and not poly(ADP-ribosyl)ation was necessary for the stimulation of DNA synthesis by mitogens. Mitogen treatment increased concomitantly the activity of both soluble and particulate mono-ADP-ribosyltransferase, as well as the number of modified proteins. Inclusion of meta-iodobenzylguanidine (MIBG), a selective decoy substrate of arginine-dependent mono-ADP-ribosylation, prevented the modification of these proteins. MIBG also blocked the stimulation of DNA and RNA synthesis, prevented smooth muscle cell migration and suppressed the induction of c-fos and c-myc gene expression. An examination of relevant signal transduction pathways showed that MIBG did not interfere with MAP kinase and phosphatidylinositol 3-kinase stimulation; however, it did inhibit phosphorylation of the Rho effector, PRK1/2. This novel observation suggests that mono-ADP-ribosylation participates in a Rho- dependent signalling pathway that is required for immediate early gene expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Iodobenzylguanidine / pharmacology
  • ADP Ribose Transferases / metabolism
  • Adenosine Diphosphate Ribose / metabolism*
  • Angiotensin II / pharmacology
  • Animals
  • Cell Division / drug effects
  • Cell Movement / drug effects
  • Cells, Cultured
  • DNA / biosynthesis
  • DNA / drug effects
  • Dinoprostone / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Gene Expression / drug effects
  • Isoquinolines / pharmacology
  • Mitogen-Activated Protein Kinases / metabolism
  • Muscle, Smooth, Vascular / cytology*
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism*
  • Phosphatidylinositol 3-Kinases / drug effects
  • Phosphatidylinositol 3-Kinases / metabolism
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases / metabolism
  • Protein Kinase C / metabolism*
  • Proto-Oncogene Proteins c-fos / drug effects
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-fos / metabolism*
  • Signal Transduction

Substances

  • Enzyme Inhibitors
  • Isoquinolines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Proto-Oncogene Proteins c-fos
  • Angiotensin II
  • 3,4-dihydro-5-methyl-1(2H)-isoquinolinone
  • Adenosine Diphosphate Ribose
  • 3-Iodobenzylguanidine
  • DNA
  • ADP Ribose Transferases
  • Poly(ADP-ribose) Polymerases
  • Phosphatidylinositol 3-Kinases
  • protein kinase N
  • Protein Kinase C
  • Mitogen-Activated Protein Kinases
  • Dinoprostone